(18)F-FDG uptake in the colon is modulated by metformin but not associated with core body temperature and energy expenditure

PURPOSE: Physiological colonic (18)F-fluorodeoxyglucose ((18)F-FDG) uptake is a frequent finding on (18)F-FDG positron emission tomography computed tomography (PET-CT). Interestingly, metformin, a glucose lowering drug associated with moderate weight loss, is also associated with an increased colonic (18)F-FDG uptake. Consequently, increased colonic glucose use might partly explain the weight losing effect of metformin when this results in an increased energy expenditure and/or core body temperature. Therefore, we aimed to determine whether metformin modifies the metabolic activity of the colon by increasing glucose uptake. METHODS: In this open label, non-randomized, prospective mechanistic study, we included eight lean and eight overweight males. We measured colonic (18)F-FDG uptake on PET-CT, energy expenditure and core body temperature before and after the use of metformin. The maximal colonic (18)F-FDG uptake was measured in 5 separate segments (caecum, colon ascendens,—transversum,—descendens and sigmoid). RESULTS: The maximal colonic (18)F-FDG uptake increased significantly in all separate segments after the use of metformin. There was no significant difference in energy expenditure or core body temperature after the use of metformin. There was no correlation between maximal colonic (18)F-FDG uptake and energy expenditure or core body temperature. CONCLUSION: Metformin significantly increases colonic (18)F-FDG uptake, but this increased uptake is not associated with an increase in energy expenditure or core body temperature. Although the colon might be an important site of the glucose plasma lowering actions of metformin, this mechanism of action does not explain directly any associated weight loss.